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ABSTRACT
Burke, Steven Russell Alan. MS, Biological Sciences, Wright State University, 2020.
Assessment of In Vivo Muscle Force in the R6/2 Mouse Model of Huntington’s Disease
Using Newly Designed Force Rig
In this thesis, we develop a system to study in vivo muscle function in a mouse
model of Huntington’s disease that allows for the recording of muscle force by
stimulating the motor nerves or the muscles directly after a nerve block. This allows us to
distinguish between defects in the nerve, such as problems with vesicle release, and
primary muscle defects, such as altered intracellular calcium homeostasis. We
hypothesize that there are primary defects in R6/2 skeletal muscle that are separate from
neurodegeneration or defects in the CNS. In this case, we should see defects in muscle
force generation during nerve stimulation and direct muscle stimulation. If our hypothesis
is shown to be correct, this work would highlight new targets to study for the treatment of
HD. Peripheral treatments of skeletal muscle are a promising area for the treatment of
HD as motor defects are debilitating for patients.
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I. Specific Aims
Specific Aim 1: To build a muscle force system capable of measuring in vivo muscle
force from mice. The most challenging part of developing a muscle force system is
designing a platform on which the mouse will be mounted. This platform will have to
keep the hind limb stable so that the length of the muscle does not change during the
muscle contractions. To achieve this, we will use computer automated design software to
design the platform and then 3D print it. Printing the platform will give us the capability
to make several prototypes easily and cheaply until the right design is achieved. Once
constructed, we will assess the new setup by analyzing the force-frequency relationship
and determining the twitch to tetanic ratio, which is the ratio of maximum twitch force to
the maximum tetanic contraction. Obtaining this ratio will allow us to determine if there
is any unwanted movement in the hind limb due to the design of the platform.
Additionally, we will analyze the shape of the contractile responses to look for sharp
changes in force that would indicate movement such as slipping of the suture.
If there is no movement of the hind limb during force measurements, we should
obtain a twitch-to-tetanic ratio of ≥30% and the data will tightly fit a Boltzmann
sigmoidal curve.
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Specific Aim 2: To test for muscle weakness in R6/2 skeletal muscle in vivo using
new muscle force system. To test for muscle weakness in R6/2 HD mice, we will expose
the sciatic nerve and isolate the plantar flexor muscles (lateral gastrocnemius, medial
gastrocnemius, plantaris, and soleus). Isometric muscle contractions will be recorded
with a force transducer that is connected to the Achilles tendon with a suture. This
approach was chosen so that we could record nerve-stimulated force and subsequently
direct muscle-stimulated force after blocking neuromuscular transmission with αbungarotoxin. This will allow us to differentiate between defects of the nervous system
and defects that are present in the muscle tissue itself. Recorded muscle force will be
normalized to muscle weight to obtain specific force. This will allow us to compare HD
to wild type mice as normalization will account for differences in force that are due to the
smaller size of the HD muscles. Force-frequency experiments will be performed first
with nerve stimulation, and again after blocking the nerve. First, we will compare WT
records to HD to check for muscle weakness. We will also compare nerve vs muscle
stimulated recordings to determine if any weakness we observe is a result of a nerve
defect or a primary muscle defect.
We hypothesize that HD mice have muscle weakness and therefore, we will observe
a significant downward shift in the force-frequency curve when compared to WT.
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II. Introduction
HUNTINGTON’S DISEASE
Huntington’s disease (HD) is a genetic degenerative disease that presents with
progressive cognitive and motor defects. The disease affects many areas of the brain, but
most notably the areas known as the striatum (Vonsattel et al., 1985). The striatum is
responsible for the control of smooth movement and a person’s mood (Bruce Koeppen
and Bruce Stanton, 2017). All the muscles of the body are affected. Throughout the
disease, the muscles will atrophy severely (She et al., 2011). Eventually, the affected
person will lose control of voluntary movement and will be restricted to a chair. In all
cases the disease is fatal. Unfortunately, there is currently no treatment that will prevent
or even slow the progression of the disease.
HD has been recognized as a disease as early as 1842. It was named after George
Huntington, who gave his famous description of the disease titled, “On Chorea” in 1872.
Huntington was the first to delineate the disease from other diseases of chorea. There
were some other descriptions of HD before George Huntington that noted a hereditary
form of chorea, notably by Charles Waters, Johan Christian Lund, and Groving Lyon
(Bates et al., 2014). George Huntington was in a perfect position to make his
observations of the disease. He had plenty of experience that was passed to him from his
father and his grandfather who were both physicians that had seen HD patients over their
years of practice (Bates et al., 2014). After Huntington, interest in the disease spread
across America and Europe as well as some South American countries (Marsden, 1975).
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Early research of HD was a slow and gradual process until it was better known.
Several international organizations and lay groups, which were developed by family
members of those with the disease, were instrumental in the progress of HD research over
the past 40 years (Bates et al., 2014). The World Federation of Neurology Research
Group on Huntington’s Disease was founded and first met in 1967 and has since evolved
into the World Huntington’s Congress. This organization has held meetings every two
years since its formation and has created a network of researchers around the world that
has resulted in collaboration between researchers from a wide range of disciplines (Bates
et al., 2014). Marjorie Guthrie, the wife of famous American folk singer Woody Guthrie
who famously died from HD in 1967, devoted much of her time promoting HD and
spreading awareness of the disease after Woody’s death (Bates et al., 2014).
HD is inherited in an autosomal dominant fashion so that each child of an affected
parent has a 50% chance of getting the disease (Myers, 2004). HD is an insidious disease.
A person with the gene mutation will start life perfectly normal and then at around
middle age will begin noticing subtle signs and symptoms. The age of onset varies widely
and can be hard to assess due to subtle cognitive changes that can go unnoticed (Duyao et
al., 1993). However, most patients develop noticeable motor symptoms around their
forties and fifties (Myrianthopoulos, 1966; Ridley et al., 1991) such as chorea, rigidity,
dystonia, and bradykinesia (Wells and Ashizawa, 2006).
HD is caused by a mutation in the huntingtin gene, specifically increased CAG
trinucleotide repeats at the 5’ end of the gene (The Huntington’s Disease Collaborative
Research Group, 1993). The gene codes for the huntingtin protein (Htt). It is located on
the short arm of chromosome four at position 16.3. The gene consists of a polyQ domain
4

which codes for a stretch of glutamines in the protein. If the domain is expanded beyond
36 glutamines, the carrier of the gene will develop HD (Myers, 2004). The expanded
CAG repeat in the mutated huntingtin protein forms a polar zipper in the protein that
results in protein aggregation (Perutz, 1995). Protein aggregates in many tissues are a
hallmark of HD pathology (Arrasate and Finkbeiner, 2012; Hoffner and Djian, 2002;
Scherzinger et al., 1997; Wanker, 2000). The age of onset is affected by the glutamine
repeat number. There is an inverse correlation between the two, such that the more CAG
repeats there are the earlier a person develops symptoms (Duyao et al., 1993). Once there
are more than 50 glutamine repeats the carrier will develop the juvenile form of HD
which has an earlier age of onset and death (van Dijk et al., 1986).
Chorea is the main symptom of the disease and is the main sign used for
diagnosis. Chorea consists of involuntary uncontrolled contraction of the muscles. This
results in a clumsy-looking walk and slurred speech that can be mistaken for intoxication
(Bates et al., 2014). Typically, in the early stages of HD, the muscles of the extremities
will be affected. As the disease progresses the chorea spreads to more proximal muscles
and those of the trunk of the body. When choreic movements begin they are usually so
subtle they are unnoticed by others. Eventually, they get worse and it begins to make the
affected individual clumsier and will make it more difficult to perform activities of daily
living such as walking, speaking, chewing, and swallowing. In later stages of the disease,
chorea can be overshadowed by dystonia (random involuntary muscle contractions).
Stress, anxiety, fatigue, and often caffeinated drinks can exacerbate chorea. Chorea
eventually becomes so pronounced the affected individual can no longer work and will
need family members or in-home caretakers to assist them. Due to disease onset
5

occurring in an individual’s prime career years, this situation puts significant stress on
their families. Many families will fall down economic ladders as they lose income due to
the affected individual’s inability to work, but also due to the expenses associated with
the individual’s care. The leading cause of death in HD is aspiration pneumonia
(Heemskerk and Roos, 2012). This is due to an inability to maintain the coordination of
esophageal muscles and the epiglottis. When a person with HD swallows, food can get
into the trachea and bacteria can infect the lungs. According to an analysis of 224 HD
patients by Heemskerk and Roos, many of the cases where the cause of death could be
identified died of aspiration pneumonia (Heemskerk and Roos, 2012).
There is a wide range of cognitive and psychiatric changes associated with HD.
Irritability is increased in HD. Patients can go through bouts where the smallest
provocation can result in a sudden outburst of angry or even violent behavior. Most often
this aggression is directed toward family or friends most directly involved in the patient’s
care (Bates et al., 2014). Additionally, psychomotor slowing is a feature of HD and has
been correlated to the CAG repeat number (Bamford et al., 1989; Snowden et al., 2002).
Patients will take longer to perform the same tasks that they used to. Also, the perception
of time becomes affected. These changes make it increasingly difficult to manage work
and meet deadlines, especially for those with more demanding and higher stress careers.
PERIPHERAL DEFECTS IN HUNTINGTON’S DISEASE
The most overt and noticeable symptoms of HD are chorea and muscle wasting.
Chorea being the main symptom used for diagnosis of the disease. It is not surprising that
the bulk of the research on HD has been done with the aim of further understanding
neuronal pathologies, especially with the significant psychological and behavioral
6

changes that accompany HD. It is a prevailing view that most of the peripheral defects
found in tissues such as skeletal muscle are secondary to changes in the striatum. That is
some changes, such as altered hormonal signaling from the hypothalamus, could alter
physiology in other tissues outside of the CNS. Being a result of something that happened
in the CNS, these pathologic events would be viewed as being secondary pathologies.
However, it is now known that the huntingtin gene is expressed ubiquitously
throughout the body (Hoogeveen et al., 1993; Li et al., 1993; Strong et al., 1993; Trottier
et al., 1995) and major motor defects are a hallmark of the disease. Even though much of
HD research has focused on the central nervous system (Lo and Hughes, 2011; Strand et
al., 2005; The Huntington’s Disease Collaborative Research Group, 1993; Wells and
Ashizawa, 2006), recent work has found many muscle defects that may help explain the
motor symptoms of HD (Waters et al., 2013). Supporting that muscle defects may
develop separately from neurodegeneration in humans, it has been observed that motor
symptoms preceded the cognitive symptoms in a marathon runner (Kosinski et al., 2007)
who was a carrier of the HD gene. A study of 960 patients showed that motor symptoms
were the earliest disease symptom or sign in 56% of the participants (Marder et al.,
2000).
As previously mentioned, the most noticeable issue with HD skeletal muscle is
the fact that it is significantly smaller. HD patients are weaker and skeletal muscle
wasting is often observed (Boesgaard et al., 2009; Ribchester et al., 2004), In the R6/2
transgenic mouse model of HD, hind limb muscles are 40% lighter than WT muscles
(Bondulich et al., 2017). It is not clear what the main cause of the loss in muscle mass is.
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Some have hypothesized that it is due to metabolic changes or altered myocyte
differentiation and apoptosis (Lodi et al., 2000; She et al., 2011).
It has been previously shown, by our lab, that skeletal muscle is hyperexcitable in
the R6/2 transgenic mouse model of HD, due to reduced resting currents through chloride
channels (ClC-1) and inwardly rectifying potassium channels (Kir) in the muscle
membrane (Waters et al., 2013). A recent publication examined neuromuscular
transmission to assess the relationship between muscle and neuronal defects (Khedraki et
al., 2017). Using voltage-clamp electrophysiology, Khedraki et al. found that
spontaneous miniature endplate currents, nerve-evoked endplate currents, and the quantal
content were reduced in R6/2 HD mice.
Peripheral pathology in HD is not exclusive to skeletal muscle. Many if not all
other cell types display pathologic changes in physiology, and this has been shown both
in mouse models and HD patients. Mutant Htt inclusion bodies are a hallmark of striatal
dysfunction. These inclusion bodies have now been found in peripheral tissue as well
(Orth et al., 2003; Trottier et al., 1995; van der Burg et al., 2009). Mutated Htt is known
to disrupt gene expression (Chaturvedi et al., 2009; Luthi-Carter et al., 2002; Strand et al.,
2005), which could lead to widespread dysfunction in peripheral tissues.
Cardiac tissue has significant defects in both humans and mice. Reduced cardiac
output and decreased myocardial thickness have been shown (Mihm et al., 2007; Pattison
et al., 2008), Cardiac failure occurs in 30% of patients with HD (Lanska et al., 1988).
There is also very high expression of Htt in the testes (Strong et al., 1993). This results in
decreased concentrations of testosterone and correlates with a worsening of the disease
overall (Markianos et al., 2005; Saleh et al., 2009). Additionally, there is a significant
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disruption of function in the digestive tract. In patients and mice, there is a loss of
ghrelin-producing neurons which regulate the sensation of hunger (van der Burg et al.,
2008). Decreased insulin production also occurs which leads to glucose intolerance
(Björkqvist et al., 2005; Duan et al., 2003; Farrer, 1985; Hurlbert et al., 1999; Josefsen et
al., 2008; Podolsky et al., 1972; Podolsky and Leopold, 1977). Finally, mitochondrial
dysfunction is known in several tissues, including skeletal muscle, and could underly
some of the weight loss in HD patients (Arenas et al., 1998; Ciammola et al., 2006;
Turner et al., 2007).
A growing body of evidence is suggesting that some of these peripheral defects
are not secondary to defects in the striatum. Testicular degradation develops before
reductions in testosterone or gonadotropin-releasing hormone (Van Raams donk et al.,
2007). Gonadotropin-releasing hormone is produced by the hypothalamus. If this were a
secondary pathology one would expect to see a reduction in gonadotropin-releasing
hormone before dysfunction in the testis. Additionally, concentrations of the luteinizing
hormone do not correlate to reductions in testosterone (Markianos et al., 2005). Some
studies have even shown that these peripheral defects can contribute to pathology in the
brain (Chiang et al., 2007; Martin et al., 2009).
As can be seen HD is a complex disease and many tissues and body systems are
impacted. To fully understand this disease, it is important to assess the peripheral defects
as they could be novel targets for the treatment of the disease. Our lab is focused on the
motor symptoms of HD. As has been discussed, the motor symptoms are debilitating for
patients and are the main reason that their lives are unraveled and are ultimately a major
cause of death. The main causes of death in HD are aspiration pneumonia and choking
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(Lanska et al., 1988; Sørensen and Fenger, 1992) due to the dysfunction of the muscles
involved in swallowing and chewing. In this project, we studied muscle function in the
R6/2 mouse model of HD by performing in vivo measurements of muscle force. In the
following section, we will cover the physiology responsible for muscle contraction at the
cellular level.
SKELETAL MUSCLE PHYSIOLOGY
Skeletal muscle in the body is responsible for generating the force required to
perform work such as moving, breathing, swallowing, talking, facial expression, and so
on. To perform a movement, such as picking up a glass of water, the muscle must receive
an impulse from the nerves that innervate it. The idea that nerves are responsible for
propagating the signal from the brain to the muscles dates back as far as the 2nd century
(Drukarch et al., 2018). However, the “modern” view of nerve conduction known as the
“neuron doctrine” began to be developed in the late 19th century. Luigi Galvani in 1791
made an accidental discovery that electric current can excite nerves and cause muscle
contraction in frog legs (Galvani, 1791). In subsequent experiments, he demonstrated that
there is an electrical force in animal tissue that is responsible for the contraction of
muscles. Using a galvanometer Emil du Bois-Raymond measured the first “action
potential” (AP) in frog nerves by noticing a negative voltage deflection when the nerve
was excited with respect to a region at rest (Du Bois-Reymond, 1884).
As with many discoveries, the electrochemical basis of nerve conduction and
muscle contraction was dependent on incremental advancements of technology and
experimental techniques. The development of the light microscope and advancements in
histological preparation allowed for early neuroanatomists to visualize neurons in greater
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detail. Importantly, Ramón y Cajal, now known as “the father of modern neuroscience”,
utilized staining techniques, developed by Camillo Golgi, that allowed him to make
marvelous depictions of nerves in the 1880s that included the cell body, dendrites, and
axons in stunning detail. His work made it possible for Sherrington to develop the
concept of the synapse in 1897 (Smith, 1996). The prevailing theory at the time was that
nerves formed an interconnected network instead of being discrete separated cells
(Drukarch et al., 2018).
In 1938, John Young performed important experiments showing that the giant
axons of the squid were in fact motor neurons (Young, 1938). Their stimulation cause
contraction of the muscles of the mantle of the squid. These giant axons were perfect at
the time to allow for electrical recordings to study the function of these nerves. This was
the beginning of the field of electrophysiology. The recording electrodes at the time were
too big for intracellular recordings in most other cells. Much of the pioneering work on
the electrical properties of nerves were done in these giant axons. Hodgkin and Huxley
saw the benefit of the giant axons and for the first-time recorded APs from the inside of
the nerve in 1939 (Hodgkin and Huxley, 1939). This work led to the formulation of
Hodgkin and Huxley’s current equation, which allowed for the quantitative assessment of
nerve properties under various conditions (Hodgkin and Huxley, 1952a). Hodgkin and
Huxley were ultimately awarded the Nobel Prize for this work in 1963.
The aforementioned Andrew Huxley as well as Hugh Huxley showed
coincidently that the actin and myosin proteins that make up a muscle fiber slide across
one another to cause muscle shortening (Huxley and Niedergerke, 1954; Huxley and
Hanson, 1954). This work paved the way for the sliding filament theory of muscle
11

contraction. At the time, the prevailing view was that muscle contracted by the folding or
coiling of various proteins within the muscle fiber.
It was not until the development of the electron microscope that the complete
picture of muscle contraction was resolved. Electron microscopy in conjunction with xray crystallography was used to decipher the 3D structures of the various protein
channels in the muscle membrane. Once these structures were determined their various
functions and gating mechanisms were determined. In the following paragraphs, we will
discuss the physiological events that take place to cause a muscle contraction starting
with the generation of an AP and ending with the process known as excitationcontraction (EC) coupling. We will also discuss the various proteins involved in the
process and how they work to ultimately cause muscle contraction and then relaxation.
The electrical impulse that travels along the axon of a nerve is known as an AP
(Hodgkin and Huxley, 1952a). All cells in the body have a membrane composed of a
phospholipid bilayer (Gorter and Grendel, 1925). This membrane is impermeable to
charged particles called ions (Na+, K+, and Ca2+ being the important ones for the process
being discussed here). The ions are held at varying concentrations inside and outside the
cell and create an electrochemical gradient (Bernstein, 1912) that can be harnessed to
perform work within the cell. Also present in the cell membrane are various proteins that
act as channels for the ions allowing them to move from one side of the membrane to the
other down their electrochemical gradient (Danielli and Davson, 1935; Neher and
Sakmann, 1976). The AP that travels down the motor nerve causes a depolarization that
is due to the opening of Na+ channels on the membrane (Overton, 1902). The Na+
channels are voltage sensitive meaning that a change in the voltage difference between
12

the voltage on the outside of the membrane and the inside in the vicinity of that channel
will cause the channel to open and allow Na+ to flow into the cell. This makes the
membrane potential more positive and the other Na+ channels in the vicinity will also
open. This is what allows the AP to propagate down the axon to the nerve terminal. The
AP will originate in nerve bundles located in the ventral horn of the spinal cord (Hong
and Etherington, 2011). The impulse travels down the axons until it reaches the nerve
terminal which forms a synapse with the muscle fiber membrane known as the
neuromuscular junction (NMJ) (Kühne and von Voit, 1886).
Once the impulse reaches the NMJ, voltage-sensitive Ca2+ channels open in
response to the AP and cause vesicles in the nerve terminal containing acetylcholine
(ACh) to fuse with the membrane releasing ACh into the interstitial fluid(Couteaux and
Pécot-Dechavassine, 1970; Dale, 1914; Katz and Miledi, 1967). The membrane on the
muscle fiber directly below the nerve terminal is known as the synaptic cleft. This area of
the membrane has many nicotinic ACh receptors that bind ACh. The binding of ACh to
the receptor causes Na+ to enter the muscle fiber and depolarize the muscle membrane
(Fatt and Katz, 1951; Neher and Sakmann, 1976b). This causes APs to propagate down
the muscle fibers of the muscle starting a cascade of events that eventually leads to
muscle contraction. This whole process is known as excitation-contraction (EC) coupling.
To fully understand this process, we must first look at the organization of muscle starting
at the level of the whole muscle and going all the way down to the individual muscle cell.
Muscles are made up of many small fibers that can stretch the length of an entire
muscle. The muscle fiber is a single muscle cell. The muscle cell or myocyte is made up
of repeating contractile units called a sarcomere (Bowman and Todd, 1840;
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Leeuwenhoek, 1710). A sarcomere is a meshwork of different proteins that can work
together to contract in response to the muscle AP. The sarcomere is made up of actin and
myosin proteins which are known as thin and thick filaments, respectively as well as
some other proteins that work as the framework of the sarcomere (Hanson and Huxley,
1953; Huxley and Hanson, 1954). Thick and thin filaments are known as myofibrils.
Actin is anchored to the Z-line of the sarcomere by a protein called titan (Kuroda and
Maruyama, 1976; Wang et al., 1979). The Z-line is the border of the sarcomere and there
is a Z-line on each end of the sarcomere. Many parallel actin filaments stretch from each
Z-line toward the middle of the sarcomere. In between each actin filament are the thick
filaments. They start at the midline of the sarcomere and stretch toward the Z-line. This
organization of myofilaments is what gives skeletal muscle its striated appearance. The
actin filament is a braided fiber of actin molecules (Holmes et al., 1990). The fiber has
many binding sites for myosin. These sites, in the resting state, are covered up by another
protein called tropomyosin. This protein has binding sites for Ca2+ so that when
intracellular Ca2+ ([Ca2+]i) rises Ca2+ binds to tropomyosin and causes a conformational
change in the protein so that it uncovers the binding sites for myosin (Spudich et al.,
1972; von der Ecken et al., 2015). This will allow myosin to bind to actin so that crossbridge cycling can begin which will lead to muscle contraction.
Along the muscle fiber membrane, regions of the surface membrane fold inward
toward the fiber interior to form narrow tubes. The system is known as the transverse
tubular (t-tubular) system and is continuous with the surface membrane (Huxley and
Taylor, 1958; Porter and Palade, 1957). The t-tubules are essential for coordinated
sarcomere shortening across the entire fiber. They allow for the AP to propagate into the
14

center of the fiber so that the entire muscle fiber receives the signal to contract. Also, the
t-tubules contain the voltage-sensitive dihydropyridine receptors that are mechanically
coupled to L-type Ca2+ channels (ryanodine receptors) on the membrane of the
sarcoplasmic reticulum (Curtis and Catterall, 1984; Inui et al., 1987). The sarcoplasmic
reticulum is the reservoir for Ca2+ in the myocyte. Once the AP reaches the
dihydropyridine receptors they undergo a conformational change that causes the
ryanodine receptors to open and allow for the release of Ca2+ into the cytoplasm of the
cell (Endo, 2007; Weber and Herz, 1968). This rise in [Ca2+]i ultimately leads to muscle
contraction. The t-tubules are lined up over the Z-lines of the sarcomere. This ensures
that Ca2+ is released in the vicinity of tropomyosin so that the Ca2+ will bind and
uncover the binding sites for myosin.
Myosin has a globular head and a tail domain. (Rayment et al., 1993). The head of
the myosin protein contains an ATPase. This enzyme will hydrolyze ATP to ADP and
phosphate (Lymn and Taylor, 1971). This chemical reaction is what releases the energy
necessary to perform the mechanical work required for the shortening of the sarcomere.
During contraction, this process is happening repeatedly so that all the myosin heads are
“walking” along the actin filament toward the Z-lines. This is known as the sliding
filament theory (Finer et al., 1994; Gordon et al., 1966; Huxley and Niedergerke, 1954;
Huxley and Hanson, 1954; Toyoshima et al., 1987). This process will continue until no
more APs come from the motor nerve. At this point [Ca2+]i will begin to be pumped back
into the SR via the SERCA pump (Toyoshima et al., 2000). Thus, [Ca2+]i will decrease to
resting myoplasmic levels. Ca2+ will fall off tropomyosin causing the binding sites for
myosin to be covered. ATP binding to the myosin ATPase causes the head of myosin to
15

unbind from actin. This causes relaxation of the muscle and the return to resting muscle
length and tension.
MUSCLE FORCE EXPERIMENTS
Given the known defects at the neuromuscular junction and in channels on the
muscle fiber membrane of R6/2 mice, we hypothesize that muscle function is affected by
these defects and will, therefore, be weaker than their wild type littermates. To test this
hypothesis, we measured muscle force in vivo in the R6/2 mouse model of HD. It has
been shown using ex vivo techniques that HD muscle is 75% weaker than WT muscle
(Hering et al., 2006). In this study muscle force from extensor digitorum longus (EDL)
and soleus muscles (hindlimb dorsiflexor and plantar flexor muscles) was measured using
ex vivo techniques. These experiments were performed at room temperature. Our
experiments were be performed in vivo at physiological temperatures, which could result
in significantly different muscle force as was previously reported. Muscle force is known
to be reduced at room temperature (Caremani et al., 2019), and it is unknown if this
temperature effect will impact muscle force differently between WT and HD.
Gillian Bates, part of the team that developed the R6/2 mouse line, and a team of
researchers tested muscle force in R6/2 mice in 2015 (Mielcarek et al., 2015). They also
showed that muscle force is reduced in HD mice when compared to WT, but only by
25%. They measured muscle force in both the tibialis anterior (TA) and EDL using in
vivo techniques. In this study, raw muscle force was given in grams of force. The muscle
force was not normalized to muscle size in any way. As one would expect a smaller
muscle should produce less force than a larger muscle. So, the question at hand is
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whether HD is truly weaker than WT once this reduction in muscle mass has been
accounted for.
As Hering et al. and Mielcarek et al. have shown differing results, we thought it
was worthwhile to revisit muscle force in the R6/2 mice. Both studies used hind limb
muscles, but they used only single muscles in their recordings. We plan to use the whole
group of plantar flexor muscles that attach to the Achilles tendon. Like the Mielcarek
study, we performed in vivo measurements while the mouse is anesthetized. We also
recorded muscle force in response to nerve stimulation and direct muscle stimulation
after application of α-bungarotoxin (BTX) to assess nerve and muscle function directly.
Finally, after muscle force recordings we muscle weight was collected so that the force
records could be normalized to muscle weight to account for differences in muscle size
between HD and WT.
To obtain isometric muscle force recordings in vivo, we first built a system to do
so. The in vivo system was built using a combination of commercially available
equipment as well as a custom platform to which the mouse can be secured during the
experiments. It was key to secure the hind limb of the mouse to eliminate any movement
during muscle contractions. Any movement during contractions will result in unstable
recordings and will prevent the successful detection of peak force during twitch and
tetanic contractions. It will also make it difficult to maintain optimal length during the
experiment. We utilized both computer automated design software and fused deposition
modeling 3D printing to allow for rapid prototyping of the force platform.
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III. MUSCLE FORCE SYSTEM DEVELOPMENT
EXPERIMENTAL GOALS AND CONSIDERATIONS
As previously stated, specific aim 1 of this this was to design and build a muscle
force system to take isometric force measurements from R6/2 hind limb muscles in vivo.
In this section, we will cover the important factors that were considered before designing
the system to achieve this goal. In the following section, the actual components of the
muscle force system will be described as well as the design process. Additionally, some
preliminary data from the various prototypes will be shown and discussed.
The choice of in vivo recordings was made to study muscle force in conditions
that are as close to physiological as possible. Additionally, we wanted to be able to
perform nerve as well as direct muscle stimulated muscle contractions after applying
BTX. This technique is important to be able to identify problems related to
neurotransmission in the nerve terminal and synaptic cleft. Additionally, comparing
direct muscle stimulated force with nerve stimulated force allows for the identification of
altered muscle properties directly that are independent of nerve function.
The muscles that we chose to record from are the plantar flexor muscles, which
include the lateral and medial gastrocnemius, plantaris, and soleus. These muscles are
part of a whole muscle group that attaches to the calcaneal bone by the Achilles tendon.
This prep has the advantage of studying the muscles as a functional group as they are
used during locomotion. As stated before, the aspect of performing these experiments in
vivo means that the muscle was maintained at 37 ˚C as it would be in the intact animal.
There are known differences in cellular physiology at room temperature vs. physiological
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temperature. Performing experiments at room temperature will slow down enzyme
kinetics and could reduce things like myosin light chain phosphorylation which will alter
muscle function. We wanted to minimize these effects in our prep. Finally, in vivo
conditions maintain normal blood perfusion to the muscles as the muscle remains
connected to its blood vessels. In ex vivo experiments the muscles need to be bathed in a
physiological buffer solution. In the prep discussed here, this is unnecessary.
We planned to perform recordings of isometric muscle contractions from the
plantar flexor muscles. To get accurate results of peak muscle force we must keep the
muscle fixed in place and assure there are no movements in either the hind limb or mouse
during the muscle contraction. To achieve this, we went through a lot of trial and error in
our methods of securing the mouse and the hind limb to the platform on which the mouse
is mounted. We also needed a way to achieve the optimal length of the muscles we were
recording from. To do this we mounted the mouse platform to a micromanipulator that
can move the platform so that the muscle is either stretched or relaxed when attached to
the lever of the force transducer. Peak muscle force at a given frequency can only be
achieved when the muscle is at an optimal length. This is the resting tension of the
muscle in which the sarcomeres are arranged in such a way that the most cross-bridge
cycling can occur while still having room for the sarcomere to shorten. If during a
contraction the mouse or hind limb moves toward the force transducer the length of the
muscle will no longer be optimal, and you will no longer be recording the true peak force
of a contraction. Additionally, you will see a drop in the baseline, or resting tension, in
between recordings.
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In early experiments we noticed that, not only would the mouse move, but the
suture securing the tendon to the lever of the force transducer can also slip. This causes
the same issues mentioned in the previous paragraph. However, instead of the limb
moving toward the force transducer during the muscle contraction, you are now unable to
maintain the proper tension on the muscle and therefore the muscle is no longer at
optimal length for the following recordings. The final issue regarding muscle tension and
the optimal length is that the suture must be strong enough to oppose the force generated
during peak muscle force during tetanic contractions. If the suture is the wrong material
or is too small of a gauge it will snap during the strongest contractions. These
considerations make the choice of suture and the knots that are used very important for
the accurate assessment of peak muscle force during stimulated contractions.
Our goal was to design a custom platform that is optimized with these
considerations in mind to be used in conjunction with commercially available recording
hardware and software. Before the development of this system, our lab specialized in
skeletal muscle electrophysiology. For these experiments, we used a digitizer from
Molecular Devices as well as their suite of recording and analysis software called
pClamp. Due to our familiarity and expertise in setting up and using this equipment we
decided to use Molecular Device’s digitizer and software for the muscle force system.
The only other recording equipment we needed to add was the force measurement
hardware. To record muscle force, we needed a force transducer. Most force transducers
measure muscle force using an analog signal such as voltage. This signal must be able to
be sent to the amplifier and then to the digitizer to be sent to the computer. Additionally,
we wanted a force transducer that is capable of recording isometric, isotonic, as well as
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eccentric muscle force. Although we are only concerned with isometric force
measurements for this thesis, we wanted the ability to perform other experiments later.
Finally, to complete the system we needed a way to deliver anesthesia to the mice.
It is very important to be able to accurately control the sedation of the mouse during these
experiments. These experiments can be well over an hour in length, especially with more
complex stimulation protocols. Therefore, we needed a system that can keep a mouse
stable under anesthesia for the duration of the experiment. It is also very important to
maintain the body temperature of the mouse while it is anesthetized. The core
temperature of a mouse is 37 ˚C. We needed our system to be able to measure and
maintain the body temperature simultaneously with a temperature probe and a heat
source.
IN VIVO MUSCLE FORCE SYSTEM OVERVIEW
The muscle force system can be broken down into five main parts: life support,
the surgical platform, the muscle force platform, the data acquisition hardware, and the
peripherals. A diagram of the system's main components is shown in figure 1 and each
part will be broken down and described in this section.
Arguably, one of the most important parts of this system is life support. As these
experiments were performed in vivo, the animals had to be maintained in a sedated state
during the entire experiment. Nothing is more important than the welfare of the animal
during these experiments. Anesthesia must be delivered in a way so that we can perform
our experiments and cause no harm or suffering to the animal. It has been well
established how to safely administer anesthesia to animals during experimentation (Kohn,
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1997) and all the experiments in this thesis were performed while strictly following
procedures and protocols approved by the Wright State IACUC committee. The
anesthesia system that was ultimately chosen was the Somnosuite low flow anesthesia
machine from Kent Scientific. This system checks all the major boxes that we need with
some additional features.
The Somnosuite allows you to deliver isoflurane in a controlled way as well as to
monitor and maintain body temperature with a built-in temperature probe and a heating
pad. The system has a digital screen that allows you to monitor the isoflurane flow rate
and concentration. To deliver isoflurane we are using 99% O2 as opposed to room air,
which can also be used with the SomnoSuite. We found that 99% O2 worked better to
maintain the HD mice during longer experiments. The SomnoSuite can also send the
temperature signal to our digitizer so that we can have a recording of animal temp during
our entire experiment. The machine includes a heating pad that can automatically
regulate body temp when used with the temperature probe. However, we only use the
heating pad to preheat the surgical and force platforms. As you will see later the built-in
heating pad is not able to be used during the surgery and force measurements because we
place pins through the paws into the platforms. To solve this issue used a lamp with a
ceramic heat bulb on a boom arm to provide heat to the mouse while anesthetized. The
boom arm allows the heat lamp to be moved from the surgical platform to the muscle
force platform as needed. To maintain 37 °C the core temperature of the mouse is
monitored with the temperature probe and the height of the lamp is manually adjusted.
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Figure 1: In Vivo Force System Diagram The in vivo muscle force system functions through the
coordination of five smaller systems; life support, surgical platform, force platform, peripherals, and
acquisition hardware. Included is a list of the unique components of each system. The arrows highlight
how each of the systems function together to obtain in vivo force data.
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One of the great features of the Somnosuite is that it was designed specifically for
small animals. The alternative options, such as traditional veterinary vaporizers are made
to be used with a wide range of animals with a wide range of sizes. This means that for
small animals like mice, conventional vaporizers are very inefficient and put out more
gas than the lungs of the mouse will ever utilize. This is where the low flow aspect of the
Somnosuite is very advantageous. The system drastically reduces costs for isoflurane and
oxygen as much less is used during a given experiment.
A diagram of the anesthesia machine is shown in figure 2. The SomnoSuite uses a
syringe that is placed into a clamp. The syringe is filled with isoflurane which is the
anesthetic that we are using. The plunger of the syringe is depressed automatically by a
block that rides along a lead screw. The lead screw is attached to a motor so that it turns
at a given rate determined by the isoflurane concentration setting. The isoflurane is
pushed through a vaporizer block where it mixes with the O2 which is the carrier for the
isoflurane molecules. The gas is then sent to the lines that are used for inspiration. The
mouse breaths in the gas, whether it is in the induction chamber or through the face mask,
and then the exhaled air returns to the machine through the expiration lines. The waste
gas is sent through a carbon scrubber that filters vapors that are carcinogenic to the
experimenter.
The muscle force platform is where we spent most of our time and energy in the
design stage of this project. This is the only component that had to be made custom for
our experimental purposes. There are some commercially available solutions from
various companies, but they are cost-prohibitive and are not tailored to our exact needs.
Therefore, we decided to spend some time designing a custom solution. We started with a
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Figure 2: Anesthesia System The anesthesia machine being used in our muscle force system is the
SomnoSuite from Kent Scientific. It is a low flow anesthesia system that delivers precise inhalant
anesthetics at a rate optimized for small animals like mice. Isoflurane is pumped automatically from a
syringe into the vaporizer block and then vaporized anesthetic is sent through the inspiratory tubes (blue
arrows). Exhaled gas is sent back to the machine through the expiratory tubes (red arrows). The gas is
then sent out the back of the machine and through a carbon scrubber to get rid of the toxic by-products
of exhaled isoflurane. The system also features an induction chamber for anesthetizing the animal. It
also has a heating pad and temperature probe for monitoring core body temp during experiments.
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handmade prototype and ultimately went through three variations of the platform until we
developed the fourth and final version of the platform. The platform was aptly named the
Achilles after the tendon from which we are recording muscle force. The Achilles
platform and its development will be described in detail in the next section.
The data acquisition hardware is the next key component of the muscle force system. The
two main pieces of equipment are the muscle force transducer controller and digitizer.
Aurora Scientific produces a dual-mode lever controller. It can simultaneously record
muscle force and control muscle length. This gives us the ability to perform eccentric and
isotonic force measurements. The 305C is a two-channel controller so we can also use
two different force transducers with different force ranges without changing our setup.
We chose this option to be able to have an in vivo system as well as ex vivo. The force
transducers are very precise micro stepper motors. They have a variable resistor on the
shaft of the motor so that force can be measured in the form of a voltage signal. A small
lever is attached to the motor shaft. The tendon of the muscle that is being recorded from
pulls on the lever and sends an increasing voltage signal to the digitizer. The digitizer
then converts the voltage signal into a digital signal that is sent to the computer. This is
ultimately shown in the acquisition software as a force recording.
The digitizer we selected is the Digidata 1550B from Molecular Devices. It has an
array of digital inputs and outputs as well as analog inputs and outputs. These allow us to
integrate peripheral devices, such as stimulators or temperature controllers, into the
system. These can also be triggered with our computer using the digital outputs and can
be automated when used with the pClamp software. The recorded signals such as the
force measured by the force transducer are sent to the analog inputs of the digitizer. The
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1550B has a total of ten inputs and outputs, both analog and digital, which gives us many
options for adding other peripheral hardware in the future.
The only peripheral hardware essential for this project is the pulse generator that
we use to stimulate the nerve. The pulse generator that we chose is the S-900 from
Dagan. This pulse generator has many options for creating pulse trains, but we chose it
for its ability to be triggered with the computer. To create the various trains for the forcefrequency experiments, we have set the simulator to generate a 1 ms pulse and put it on
trigger mode. When the generator receives a 5 V triggering pulse from one of the digital
outputs of our digitizer it will fire a pulse. In the software, we can send out complex
trains of triggering events so that we can stimulate the nerve at any frequency for any
amount of time.
Our system also utilizes a temperature controller so that we can perform ex vivo
experiments at a physiological temperature. Additionally, we added a differential
amplifier that can record muscle compound APs during muscle contractions. This gives
us the ability to generate EMG recordings during our in vivo contraction experiments.
The numerous amounts of inputs and outputs on the digitizer gives us plenty of room for
expansion in the future.
THE ACHILLES PLATFORM
Now that we have a general overview of the muscle force system and its various
components, we will discuss the development of the Achilles platform. We developed
four versions of the platform in total. We made incremental improvements with each
version. Here, this process will be shown step by step with some preliminary data and the
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various features of the final version of the platform will be highlighted in the following
section.
The first version of the Achilles platform was hand made. We started with a
simple breadboard and a micromanipulator from Thorlabs (XR25C). The plan for
recording muscle force was to have the mouse in the prone position and the caudal end of
the mouse towards the force transducer. The plantar flexor muscles would be exposed,
and the Achilles tendon attached to the lever of the transducer with a suture (6-0 braided
silk suture was used with a modified Miller’s knot). To fix the mouse to the platform we
chose to use Sylgard (Sylgard 184, Dow Corning, Michigan, US) a silicone elastomer
that comes as a two-part kit that you mix and let cure. Once cured it is a pretty solid
elastomer with a little bit of give. To keep the mouse in place its limbs can be secured to
the Sylgard by placing pins through the paws of the mouse into the Sylgard. The platform
would need a cavity in which the Sylgard could be poured and held during the curing
process. We decided to use a culture flask which had two advantages. The first was that
we could pour the Sylgard into the flask and let it cure. The flask was mounted to the
breadboard horizontally and was cut in half so that the mouse could lay on top of a bed of
Sylgard. Secondly, the mouth of the flask gave us a surface onto which we could pin the
foot while maintaining its natural position at a 90° angle to the tibia.
Using Achilles I, we were able to collect some preliminary force-frequency data.
However, this data had some key issues that needed to be worked out. First, it was clear
that the hindlimb of the mouse needed to be secured with more than just a pin into the
Sylgard through the paw. There was some clear movement that could be detected in our
force records. Throughout the recordings breathing artifacts were present due to the hind
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Figure 3: Preliminary Force Data Artifacts Achilles I produced force data that was unreliable.
Common issues included slippage of the suture securing the tendon to the force transducer. The
record shown in panel A is an extreme case of this. The slipping of the suture can be seen by the
sudden loss of force in the middle of the trace. Black arrows are pointing to breathing artifacts due
to excess movement in the hindlimb. Many of the traces contained significant shifts in the baseline
as can be seen in A and B above.
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limb not being properly secured (Figure 3A). Additionally, after a contraction, especially
those near the maximum, a baseline shift could be detected by a reduction in resting
tension at the beginning of the following recording (Figure 3A & B). This is unacceptable
as subsequent recordings would no longer be made at the optimal length of the muscles.
To prevent this movement, we came up with a couple of solutions to fix the leg in place
during recordings.

Figure 4: Hind Limb Immobilization Achilles I & II Originally staples over the femur and ankle were pinned
into the Sylgard of the platform (A) to secure the hind limb. Later we developed a system utilizing metal
straps to secure the ankle and foot to the platform to immobilize the leg during recordings (B).

The first solution that we tried was to use a staple to pin the upper leg to the
Sylgard of the platform (Figure 4A). This worked at first, but as we learned it also created
two new problems. The first problem that was noticed was that overtime the Sylgard
began to wear out from being punctured repeatedly by the pin. This makes it porous and
allows the staple to back out during contractions. This renders the staple ineffective for
limiting unwanted movement during muscle contractions. To address this, we came up
with a way to pin the leg down in the same manner as the staple while not depending on
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the Sylgard to keep it in place. We developed a rail system in which we could clamp a
rod that had a staple on the end. This rod can then be lowered in place and clamped down
so it will not move during contractions. Additionally, we made some metal straps that
could be used to secure the foot and ankle (Figure 4B). These improvements were
integrated into the second and third versions of the platform, Achilles II and III.

Figure 5: Achilles II & III Achilles II was developed to add the metal straps that are used to secure the foot
and ankle of the mouse. Additionally, the rails system and leg clamp rod were added (A). Inserts and
holes for fasteners were also added. Finally, epoxy was poured into the bottom before adding Sylgard to
reduce the amount of Sylgard being used. Achilles II was eventually streamlined and redesigned in CAD
to be 3D printed. The 3D printed Achilles III is shown above (B).

Achilles II was also hand made. We used a micropipette tip container that we
trimmed down to size. Additionally, we added holes so that we could place threaded
inserts so that we could screw our new straps into place (Figure 5A). This prototype
provided the framework for us to make what we thought at the time would be the final
version of the platform. Achilles III was 3D modeled in CAD software and then printed
using a 3D printer (Figure 5B). This will be discussed in more detail in the paragraphs to
follow while discussing the details of Achilles IV. The rail system was made utilizing
some basic metal rods as well as some x blocks (UX-6-6) from Thor Labs. The metal
rods have tapped holes on the end so they can be secured to the breadboard that the
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platform is mounted to. The x blocks allow us to position the rod precisely over the leg so
it can be clamped down. The combination of the new rod system and metal straps
drastically reduced the unwanted movements during muscle contractions. Breathing
artifacts were essentially gone and there were no more shifts in baseline between
recordings.
As mentioned before the stapling technique presented an additional problem.
When we decided to use the staple, we failed to consider the underlying anatomy of the
upper leg. We were placing the staple over the femur. Coincidently, the femoral artery
runs along the femur. It was not until we started clamping down the leg with the rod that
we noticed that blood flow to the lower leg and thus to the plantar flexor muscles was
being constricted. The original staple was backing out and was therefore not constricting
blood flow enough for us to notice. However, the rod being clamped was so effective that
when the leg pushed against it during contractions it was able to cut off the blood flow.
With limited blood getting to the plantar flexor muscles, we noticed force decline
when performing repeated stimulation. At this point, we went back to the drawing board
to address this issue. The first and obvious issue was that the end of the rod was pushing
down on the tissue of the thigh with too much force. To ensure this was no longer an
issue we wanted to abandon clamping the leg directly secure it in place. Instead, we
decided to brace the entire rear end of the mouse. When the muscle pulls on the lever
during a contraction it also pulls on the leg. This causes the whole body of the mouse to
move toward the force transducer. Therefore, we thought that if we could limit the body
movement, we would eliminate the movement of the upper leg without having to clamp it
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Figure 6: Hind Limb Support Rods and Rail System The hindlimb needed to be secured near the hip as well
as near the ankle. The image above shows the rails system we developed to properly secure the caudal
end of the mouse and thus the upper leg. Two rods are fixed to a rail system over the platform. The rods
can be moved precisely along the x and y-axis of the platform to properly position them at the hip and
are secured in place using thumbscrews so that they do not move at all during experiments. Since we
were no longer dependent on the Sylgard for securing the hind limb we did not have to worry about
baseline shifts in force records after repeated use of the platform.

directly. So instead of using one rod clamped at the top, we used two. One was placed on
the hip area and the other was placed on the inner thigh and groin area (Figure 6).
The next thing that was done to eliminate the restriction of blood flow to the
plantar flexor muscles was to change the design of the platform itself. Blood flow is
maintained when the leg is kept in a more natural position. When a mouse is in a prone
position the leg is not stretched out flat as it has been in the first three versions of the
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Figure 7: Achilles IV In the final version of the force platform an upper platform was added for two
reasons. The fist was to raise the body of the mouse higher than the lower hind limb to maintain the
natural leg position as well as to increase blood flow. A beveled edge was added to support the upper
leg and maintain a bend in the leg while the mouse was in the prone position. The new platform was
kept as a separate part to allow for the top to be adjusted to accommodate the various leg sizes of
different mice (A). Also, goal with the final design was to reduce the amount of Sylgard used. Instead of
one large cavity with Sylgard, there are now two small cavities only where the Sylgard is necessary. The
cavity on the upper platform is for pinning the paws. The lower cavity is to for the lower limb to rest on.
Mounting posts were modeled on the bottom to allow the platform to be secured to the breadboard and
micromanipulator (B).

Achilles platform. The lateral and medial condyles of the femur protrude enough to limit
blood flow through the arteries supplying the plantar flexor muscles when the leg is
clamped flat. The next modifications to the platform were made to accommodate a
natural leg position with the leg being slightly bent. To achieve this, we added a second
platform on top of the original platform that is shorter than the base. The front of the
upper platform has an angle on its edge so that the upper leg can rest on it. The shin of
the leg then rests on a bed of Sylgard. Additionally, Achilles IV only has Sylgard in the
areas it is needed as opposed to the entire platform. There is an area for the paws to be
pinned down and an area for the lower leg to rest on. Finally, we made the upper platform
adjustable to accommodate legs of various sizes.
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Importantly, aluminum dovetail extrusions were used so that the platform and
force transducer could be precisely positioned (Figure 8A). The force transducer was
mounted on a carriage that rides on a dovetail that allows it to be positioned at an
appropriate height (Figure 8B). The suture needed to be aligned so that it pulls on the
lever of the transducer at a 90° angle so that the true muscle force could be measured.
The micromanipulator to which the force platform is mounted to also rides along a
dovetail so that it can be adjusted along the x-axis allowing us to align the suture with the
force lever (Figure 8C & D).
With these modifications, the Achilles IV has remained the final version of the
force platform. Replicable in vivo force data is reliably obtained using this system. The
R6/2 force-frequency data was collected again using this version of the platform. The
final data will be presented in the following section of this thesis. First, we will discuss
some of the advantages of 3D printing and its other applications with this system. We
will also cover some additional considerations that had to be made during the design
process as a result of 3D printing the platform.
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Figure 8: Achilles Positional Adjustment The Achilles platform and force transducer utilize aluminum
dovetail extrusions for precise positional adjustment (A). The force transducer is mounted to carriage
that uses a dovetail extrusion that allows the transducer to be positioned at the proper height for force
recordings (B). The micromanipulator (C) allows the platform to be positioned along the y-axis by being
adjusted with fine movements with the turn of a dial. The dovetail the manipulator is mounted to allows
the platform to also be moved along the x-axis so that the hind limb of the mouse can be aligned with
the lever of the force transducer (D).
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3D MODELING AND PRINTING
To design the Achilles platform before printing, it was first modeled using
parametric modeling. The software used is called Fusion 360 from Autodesk.
Conveniently, their software is free for students. Although it is free, it is a powerful
software. We were able to create a 3D model of our force platform to its exact
dimensions. Additionally, the companies that make many of the other components in our
system have made the CAD files of their components available online. After the platform
had been designed, we could model the entire system in the Fusion 360 environment
(Figure 9). Fusion 360 also has the entire McMaster-Carr catalog with CAD models of
their hardware. This was very helpful in determining all the small pieces of hardware we
would need such as the various fasteners, washers, and inserts.
The platform was modeled with the idea in mind that it would be mounted to a
breadboard on the micromanipulator. We modeled mounting posts that can accept heatset threaded inserts. Once the part is printed, the inserts can be melted into place using a
soldering iron. The inserts are knurled on the sides so that they create a strong bond with
plastic as it cools. The platform can then be placed on the breadboard and fastened into
place using metric hex screws. We also used this technique for fastening the metal straps
for securing the ankle and foot in place on the platform. The straps we used were cut out
of a sheet of stainless steel and were cut into shape using a rotary tool and cutoff wheel.
Holes were drilled in each end for the screws.
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Figure 9: Platform Modeling and 3D Printing The final version of the force platform, Achilles IV, was
modeled using Fusion 360 from Autodesk. Many of the companies that make the various components in
this system (Thorlabs, Newport, and Misumi) make the CAD files of their products available online. This
makes it possible to quickly model the entire system in Fusion 360.
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Once the platform had been modeled, it is was time to print the parts. We decided
to print the platform using fused deposition printing. The printer has a hot end that melts
a plastic filament onto a heated print bed. It prints one small layer of the part at a time,
each layer being 200 microns thick. For the printer to do this you have to generate code to
instruct the stepper motors to move the hot end about the print bed and the filament
through the extruder. We used a slicing software called Cura 4 from Ultimaker. The
software slices the part into many 200-micron layers and generates the instructions the
printer will use to print the part. An overview diagram of the printer is shown in figure
10.
The Achilles platform was printed using PETG (polyethylene terephthalate with a
glycol modification) filament. There are many filaments available for 3D printing. Our
two main choices were either PLA (polylactic acid) or PETG. PLA is one of the most
widely available filaments. It is popular for hobbyist printers as it is very easy to print
with, especially for beginners. However, it is made from plant starch. This makes it prone
to warping from prolonged heat exposure. We needed a more heat-stable plastic since we
are heating the bed during our experiments. PETG filament costs about the same as PLA
filament but is more heat stable. It has the same ease of printing as PLA but has the
durability of ABS. ABS is widely used in the manufacturing of consumer products that
need to be very durable. However, ABS is harder to print with as it needs higher
temperatures and an enclosed printing space.
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Figure 10: Diagram of 3D Printer The printer used to print the Achilles IV platform utilizes fused
deposition modeling technology. The part is printed by a thermoplastic filament being melted through a
hot end onto a heated print bed. The printer used in this project is a core XY printer. This means that the
hot end moves along the X and Y-axis and the print bed moves along the Z axis. The hot end is on a
carriage that moves along aluminum rails. Stepper motors move the hot end around the X and Y-axis
using belts. There is also a cooling fan next to the hot end that cools the filament as it is extruded to the
filament. Parts are printed in 200-micron layers until the entire part is printed.
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Overall, printing our platform has been of great benefit. Not only for this
application but also others around the lab. Now that our lab has the skills to model parts
and print them, we can save significant costs on parts we would otherwise have to buy.
The filament for the printer is very affordable. At the time of writing this, a kg of PETG
is around twenty-five US dollars. Our force platform only takes about 200 g of filament.
Therefore, we can print several platforms with one spool. Making and maintaining parts
in the lab is cheap and easy. Also, once the parts are started on the printer the whole
process is automated. One can leave and work on other things until the part is finished.
As previously discussed, Achilles IV is the final version of the force platform.
Achilles IV is a two-part platform. The base has a small cavity for Sylgard as well as
some spaces for inserts on the top. On the bottom are the mounting posts for securing the
platform to the breadboard. There is also a channel and some fasteners that allow the
second part to adjust to different positions and be secured in place. The upper half of the
platform is 20 mm thick and has a beveled edge to accommodate the upper leg and
maintain the natural bend in the knee. It has a channel for Sylgard for the front paws to be
pinned to. Once mounted on the breadboard and used in combination with our rail
system, the Achilles IV keeps the mouse and its hind limb very stable. Our force
recordings no longer show any shift in baseline after successive contractions.
Additionally, tetanic muscle force no longer declines after repetitive tetani protocols, as
the platform has been optimized to maintain maximal blood flow (Data not shown as it
was performed after the completion of this thesis)
According to our analysis, we were able to significantly improve the platform.
Figure 11A shows that from Achilles II to Achilles IV the steady decline in resting
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Figure 11: Assessment of Platform Improvement Early versions of the force platform produced force
records that showed continual baseline decline throughout successive recordings. Achilles II showed
significantly more baseline decline throughout force-frequency recordings than Achilles IV (A). Percent
decline and twitch to tetanic ratio were both significantly decreases by the improvements made to
Achilles IV (B). Significance assessed with Student’s t-test. Values are shown as ± SEM, n = 4 Achilles II
& 4 Achilles IV.

tension was dramatically reduced. The baseline from our first recording to the last during
force-frequency experiments would drop by almost 50% when using Achilles II. We
were able to reduce that to just over 15% with the Achilles IV platform (Figure 11B).
Additionally, we saw a significant improvement in our twitch to tetanic ratio and
achieved our goal ratio of 30% (Figure 11C).
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IV. R6/2 FORCE-FREQUENCY DATA
FORCE MEASUREMENT METHODS
For force measurements, mice were anesthetized with isoflurane using a low-flow
anesthesia system (SS-01, Kent Scientific, Torrington, CT), with body temperature
maintained at ~35 ℃ using a heat lamp and temperature probe. The plantar flexor
muscles (including the lateral and medial gastrocnemius, plantaris, and soleus muscles)
and sciatic nerve were exposed by removing the surrounding skin. To minimize the
influence of adjacent muscles, the common peroneal and tibial nerves were crushed.
During surgery, the muscles were bathed in physiological saline to prevent them from
drying out. The mice were then transferred to a custom platform filled with Sylgard and
mounted to a micromanipulator (XR25/M, Thorlabs, Newton, NJ). The leg was stabilized
to prevent movement. The proximal end of the plantar flexor muscles (Achilles tendon)
was attached to the lever of the force transducer (300D-305C dual-mode muscle lever,
Aurora Scientific, Ontario, Canada) using 5.0 or 6.0 silk suture and a modified Miller’s
knot. The optimal length was obtained by measuring the maximum twitch force while
lengthening the muscle using the micromanipulator.
Nerve-evoked contractions were stimulated with platinum electrodes resting on the
sciatic nerve. Direct muscle contractions were stimulated via platinum electrodes
positioned above and below the plantar flexor muscles. Stimulus amplitude and the pulse
width were determined by ensuring maximal twitch force was achieved. These values were
typically ≤5 V at 1 ms or ≤50 V at 1.5 ms for nerve-stimulated and muscle-stimulated
contractions, respectively. For muscle stimulated contractions ~150 µl α-bungarotoxin was
injected intramuscularly. Nerve stimulated twitch force was assessed until it was reduced
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to ≥25% of max. A Dagan S-900 Stimulator and S910 Stimulus Isolation Unit was used
for stimulation. Muscle force was recorded and digitized using pClamp10 software
(Molecular Devices, San Jose, CA). After each experiment, the muscles were quickly
weighed and then frozen in isopentane cooled in liquid nitrogen. The muscles were stored
in a –80 ℃ freezer until needed for further analysis.
EXPERIMENTAL MICE
R6/2 mice were studied at end-stage HD and compared with age-matched
littermates. Selection criteria were based on a combination of behavioral changes and
weight loss based on daily checks after 10 weeks of age. Mice were taken once body weight
loss reached 20% - 25% of max body weight. Animals are housed in the laboratory animal
resources facility at Wright State University. They are kept in cage racks with littermates
of the same sex. Once HD mice reach 10 weeks of age, they are given moist chow on the
cage floor daily.
STATISTICS
A repeated measures ANOVA was run to compare WT vs HD muscle force at
twitch force and 100 Hz. This was performed for both nerve and direct muscle stimulated
force. The repeated measure accounts for potentially correlated results that can arise from
the fact that it is the same mouse being measured at each of the two frequencies. SAS
version 9.4 (SAS Institute, Inc., Cary, NC) was used for all analyses. Bonferonni multiple
comparison procedure was used to control for a potentially inflated type I error rate
(claiming a significant difference exists when it does not) that can result from making
multiple comparisons. This procedure ensures that the type I error rate for the repeated
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measures ANOVA is at most α = 0.05. Student’s t-tests were used where otherwise
mentioned.
FORCE-FREQUENCY DATA
To complete specific aim 2, a force-frequency protocol was developed so that
muscle force could be recorded at increasing frequencies. The protocol for each
frequency featured a train of ten 1 ms pulses. Muscle force was recorded at a range of
frequencies from 0.3-100 Hz. In all experiments, nerve stimulated contractions were
performed first at all frequencies before moving to direct muscle stimulated contractions.
Throughout all recordings, stimulus amplitude and pulse width were held constant. Once
the platinum stimulating wires were placed on the sciatic nerve, the stimulus threshold
was found by increasing the pulse amplitude until a twitch was generated. The stimulus
was then increased by 20% to ensure that the stimulus remained above the threshold after
multiple rounds of stimulation. The force platform was then adjusted using the
micromanipulator so that optimal muscle length was reached. The optimal length was
determined by stimulating a single twitch and then increasing the tension on the muscle
by moving the platform 10 µm away from the force transducer and then stimulating
another twitch. The peak force is assessed for each twitch while increasing resting muscle
tension. This was repeated until the maximum twitch force was achieved. At this point,
the muscle was rested for ten minutes before proceeding with force-frequency recordings.
A total of 6 WT and 4 HD mice were recorded. Peak force during the train was
taken for each animal and then averaged for each genotype and data are presented as ±
SEM. The average peak force for each frequency was added as a single point on the
force-frequency graph. The points were then fit with a Boltzmann sigmoid curve
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according to the following equation (𝑦𝑦 =

𝐴𝐴1 −𝐴𝐴2

1+𝑒𝑒 (𝑥𝑥−𝑥𝑥0 )/𝑑𝑑𝑑𝑑

+ 𝐴𝐴2 , 𝐴𝐴1 is the initial value and

represents the bottom plateau of the curve, 𝐴𝐴2 is the final value and represents the upper

plateau of the curve, 𝑥𝑥0 is the midpoint of the curve and represents the frequency of half
max or f1/2max). Raw traces are shown for twitch and tetanic contractions (Figure 12A).
As expected, as the stimulation frequency increases the force also increases due to

summation. When looking at raw muscle force, our data is consistent with previous
reports (Hering et al., 2006; Mielcarek et al., 2015). When compared to WT muscle force
HD mice produce significantly less force at low and high frequencies (Figure 11B & C).
However, at 30 Hz there is no significant difference between HD and WT raw force. This
is likely due to the left shift in the force-frequency curve. As such, muscle force at 30 Hz
is closer to maximum tetanic contraction for HD than for WT.
Due to the known atrophy present in HD, it is important to normalize the muscle
force to account for the difference in muscle size. To do this we normalized muscle force
to muscle weight for each animal. Raw traces for specific force are shown in figure 12A.
The normalized muscle force is called specific force. Looking at the specific force of the
R6/2 muscle tells a completely different story than raw force. At all frequencies along the
force-frequency curve, HD produces significantly more force than WT when normalized
to muscle weight (Figure 12B & C). In the following section of this thesis, we will
discuss some different possibilities as to why HD muscle is producing more force than
WT muscle. This result was not expected. However, this has not yet been studied using
the in vivo techniques presented here. The only other report on in vivo muscle force in the
R6/2 line showed a reduction in raw force at both twitch and maximum tetanic
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Figure 12: Raw Force-Frequency Data: Raw traces for twitch, 30 Hz, and 60 Hz are shown (A). Muscle
force increases with stimulation frequency due to summation. WT muscle produces more force than
HD at low and high frequencies (B). Twitch force and tetanic force at 100 Hz are significantly reduced
in HD. Frequency of ½ max is significantly reduced in HD by 14 Hz compared to WT. All p-values >
0.001, repeated measures ANOVA. Significance shown for frequency of ½ max using a Student’s ttest. Values are shown as ± SEM, n = 6 WT & 4 HD (C).
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contraction (Mielcarek et al., 2015). However, these results were not normalized and
cannot be directly compared to our data.
Muscle stimulated force was slightly lower than nerve stimulated force for both
WT and HD as expected. It is very hard to get 100% of nerve stimulated force when
stimulating the muscle directly. This is because the muscle is a very thick tissue
compared to the nerve. It takes much less voltage to stimulate the entire nerve maximally.

Figure 13: Nerve Stimulated Specific Force-Frequency Raw traces of specific force are shown for twitch, 30
Hz, and 60 Hz stimulation (A). When normalized to muscle weight, R6/2 muscle produces significantly more
force at all frequencies throughout the force-frequency curve, p-value = 0.0032, repeated measures ANOVA
(B & C). Values are shown as ± SEM, n = 6 WT & 4 HD.

The direct muscle stimulated contractions also showed higher force than in HD
than WT (Figure 13A). However, when looking at the muscle stimulated force-frequency
curve for HD, a plateau can be noticed from 60 Hz on. In WT the force continues to
climb. We hypothesize that HD muscle is more prone to fatigue. All the different
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frequencies were recorded one after another. We started at 0.3 Hz and worked through
every frequency until we reached 100 Hz doing all nerve stimulated contraction before
moving on to direct muscle stimulation. This means that by the time we started the
muscle stimulated contractions we had stimulated ten trains. Once we started direct
muscle stimulation and reached 60 Hz, we the muscle had endured 17 trains of 10 pulses
each. We believe that the cause of the dip in the muscle stimulated force curve in HD
muscle is due to fatigue caused by the preceding trains.

Figure 14: Muscle Stimulated Force-Frequency To test for potential muscle fatigue due to repetitive
stimulation the twitch to tetanic ratio was analyzed in nerve and muscle stimulated force (A). Twitch to
tetanic ratio was significantly increased (Student’s t-test) in the HD muscle stimulated force-frequency
curve. Due to this the muscle stimulated force-frequency curve plateaus at 60 Hz and beyond in HD (B).
Values are shown as ± SEM, n = 6 WT & 4 HD.

To test this, we compared the twitch to tetanic ratio of HD to WT for both nerve
stimulated contractions and muscle stimulated contractions (Figure 14). We see that there
is a significant difference in the twitch to tetanic ratio between HD and WT for direct
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muscle stimulated contractions but not for nerve stimulated contractions. Since the
muscle was able to produce enough force to get a lower twitch to tetanic ratio when
stimulated with the nerve, we believe that the muscle has been fatigued due to repeated
stimulation.

Figure 15: Fusion Index Fusion index was analyzed at 50 Hz which is near the middle of the forcefrequency curve. This is important because you need a partially fused tetanic contraction to assess the
fusion index. Fusion index is a measure of the average Antipeak to the average peak (A). Each peak
within the tetanus is averaged as well as the antipeak. Avg fusion index is shown for both HD and WT
(B). Values are shown as ± SEM, n = 6 WT & 4 HD.

Finally, we noticed a different level of fusion between WT and HD tetanic
contractions. As the frequency of stimulation increases, there is less time for the muscle
to relax in between each stimulus. Therefore, a ten-pulse train at 40 Hz produces more
force than a ten pule train at 20 Hz. This is known as summation. The level of fusion in
each tetanus can be measured by finding the ratio of the antipeak to the peak. This is
called the fusion index. A fusion index of one would be a fully fused tetanic contraction.
We analyzed the fusion index for each frequency in both HD and WT. The fusion index
in HD was significantly higher than WT (Figure 15).
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V. Discussion
Through the work described in this thesis, we have shown that peripheral defects
are important to HD pathology. Our data suggest primary muscle defects may be a key
component of the observed muscle defects in HD patients. It is clear that defects in the
CNS are of importance as well to disease progression and symptomology. However, it is
necessary to fully assess defects in all peripheral tissues, not just skeletal muscle.
Furthermore, it is important to look at these defects rigorously and to assess if they are
primary in nature. Peripheral defects would be the key to unlocking accessible targets for
the treatment of HD.
The motor symptoms that occur in patients with HD are debilitating as the disease
progresses. They eventually make it impossible for the affected individual to perform the
simple activities of daily life that most take for granted. If the motor symptoms could be
prolonged or tamed in some way, the quality of life and outlook for the patient would be
greatly improved. Potentially, the life expectancy of those with HD could be increased as
many patients die due to dysfunction in various muscles (muscles of mastication and
swelling, as well as the heart, are most important).
The data presented here makes it clear that there are indeed muscle defects in
R6/2 skeletal muscle function. These defects need to be further explored as we have not
determined the precise mechanism underlying these defects. However, in the following
sections, we will discuss some possible physiological mechanisms that could be altered
based on our data.
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ALTERED NEUROTRANSMISSION
Our lab previously assessed neurotransmission in R6/2 mice and found altered
neurotransmission including reduced quantal content and both spontaneous and evoked
endplate potentials (Khedraki et al., 2017). This was shown to be due to a reduced
probability of release of vesicles in the nerve terminal. This data is what led us to
hypothesize that muscle force would be reduced in R6/2 muscle. We observed increased
specific force in response to both nerve and direct muscle stimulated contractions.
Therefore, it is unlikely that altered neurotransmission is impacting muscle force at least
during the brief stimulations that are performed to collect the force-frequency data. If
altered neurotransmission were altering the muscle force, we would expect to see the
reduced specific force with nerve stimulation but not when stimulating the muscle -/directly after application of BTX.
Recently, we published a paper using the force platform that was developed in
this thesis. In this paper, it was shown using BK-/- mice that the absence of BK (big
conductance potassium) channels in the nerve terminal alters neurotransmission (Wang et
al., 2020). This work highlights how our technique can show nerve defects in muscle
force recordings. Nerve stimulated force, in this case, was significantly reduced in BK-/mice compared to WT littermates (Figure 16) but not direct muscle stimulated force.
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Figure 16: Reduction in Muscle Force Caused by Altered Neurotransmission Shown here is an example of
how the Achilles IV was put to use to find the cause of muscle weakness in mice lacking big conductance
K+ (BK) channels. (A) Representative specific force traces from wild type (black) and BK–/– (red) muscle
showing twitches (top panel) and responses to 30 Hz (middle panel) and 60 Hz (bottom panel) stimulation
for both nerve stimulation (left column) and direct muscle stimulation (right column). (B) Bar graph
showing twitch specific force for nerve and muscle stimulation. Values shown as mean ± SEM, * indicates
a p-value < 0.05, one-way ANOVA. (C) Specific force-frequency curves, fitted with a Boltzmann equation,
for WT nerve (black solid line) and muscle (black dashed line) stimulation as well as BK–/– nerve (red
solid line) and muscle (red dashed line) stimulation. Values are shown as ± SEM, n = 4 WT and 6 BK–/–
mice.
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CONTRACTILE MACHINERY MODIFICATIONS
Contractile filament alteration could play a role in the increased specific force in
R6/2 muscle. Regulatory proteins are present in both myosin and actin and different
isoforms and levels of expression for both have been shown (Bozzo et al., 2003; Gordon
et al., 2000; Schiaffino and Reggiani, 1996). Myosin light chain (MyLC)
phosphorylation alters contractile filament sensitivity to [Ca2+]i (Schoffstall et al., 2006).
When MyLC is phosphorylated, the binding affinity for Ca2+ is increased and force
production is increased (Bozzo et al., 2005).
A complete review of all these contractile filament regulatory proteins as well as
their transcriptional modifications is beyond the scope of this thesis. However,
remodeling of contractile filaments and regulatory proteins could be affecting R6/2 force
production. Mutant Htt is known to interact with intracellular proteins and alter gene
expression. These protein interactions still need to be explored, especially in skeletal
muscle.
ALTERED INTRACELLULAR CALCIUM HOMEOSTASIS
The proper transport and handling of [Ca2+]i is very important for muscle
contraction in response to APs. We have talked about the release of Ca2+ through the
opening of ryanodine receptors in the SR membrane. Previous reports have shown no
change in the expression of ryanodine receptors in R6/2 muscle (Braubach et al., 2014).
Additionally, the SERCA pump responsible for pumping Ca2+ back into the SR should
also be considered. Increased Ca2+ or decreased SERCA pumps or activity could result in
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elevated [Ca2+]i. Braubach et al. assessed both and found decreased Ca2+ release with
decreased Ca2+ reuptake into the SR. They did not assess SERCA pump expression.
Interestingly, they also found increased Ca2+ entry from the extracellular space.
Our fusion index data suggest some change in Ca2+ handling during muscle
contraction. Additionally, a leftward shift in the force-frequency curve could be partially
explained by altered Ca2+ handling. Fusion occurs when Ca2+ is not completely pumped
back into the SR when the next stimulus of a train causes the ryanodine receptors to open
again. This gives less time for the force to return to baseline before climbing again in
response to the stimulus. If there is increased [Ca2+]i during muscle contraction in R6/2
mice, then more force could be produced at a given frequency than in WT muscle causing
a leftward shift in the force-frequency curve.
MUSCLE FATIGUE DUE TO REPETITIVE STIMULATION
Rarely in biological research does an observed change in physiology happen in
isolation. Increased force output, on one hand, could be viewed as being advantageous,
but on the other hand, it will likely come at a cost. The direct muscle stimulated forcefrequency curve would suggest that this is the case. In R6/2 muscle the force-frequency
curve plateaus at frequencies above 60 Hz, whereas the WT force curve continues to
climb. We believe that we caused the R6/2 muscle to fatigue due to the repeated
stimulation that was performed to collect the data needed for two force-frequency curves
in succession.
The twitch to tetanic data supports this notion. The twitch to tetanic ratio for the
nerve stimulated curve in R6/2 muscle was not significantly different than WT. We were
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able to obtain a ratio of around 30% for both R6/2 and WT during nerve stimulation.
However, the twitch to the tetanic ratio for the muscle stimulated curve in R6/2 was
significantly different from WT. Near the end of our experiment R6/2 muscle was
producing less tetanic force than it was earlier when we were stimulating the nerve.
Increased muscle weakness after prolonged activity fits with patient
symptomology. Patients suffer from motor impersistence (Paulson and Albin, 2011)
which is the inability to sustain a voluntary muscular effort. They also suffer from chorea
which results in irregular and jerky movements. R6/2 muscle being hyperexcitable
(Waters et al., 2013) and producing more force while being more prone to fatigue could
help explain some of these symptoms.
It would be important to perform further studies to assess muscle fatigue in R6/2
muscle. A protocol including repeated rounds of tetanic stimulation could be developed
and used to characterize the level of fatigue in response to sustained activity in R6/2
muscle. This type of stimulation protocol better mimics activities such as locomotion.
The brief stimuli of twitches and the short trains used in this study are not as relevant
physiologically to sustained activity which is important for tasks such as coordinated
movement like walking or chewing food.
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VI. Conclusions
Upon successful development of the Achilles in vivo muscle force system, R6/2
muscle function was able to be assessed by generating force-frequency curves. We found
that raw muscle force in the R6/2 mouse model of HD is reduced when compared to WT
littermates. This data is consistent with previous reports (Hering et al., 2006; Mielcarek et
al., 2015). However, when normalized to muscle weight, specific force produced by R6/2
mice is significantly higher than WT. Additionally, increased fusion index suggests that
altered myocyte Ca2+ homeostasis could be causing increased specific force in R6/2
muscle. Defects in myocyte Ca2+ homeostasis have been shown in the R6/2 line
(Braubach et al., 2014). Future research must be conducted to determine the specific
mechanisms that are responsible for the altered Ca2+ handling during muscle contraction.
Muscle fatigue was detected in the direct muscle stimulated force-frequency data.
The twitch to tetanic ratio was significantly increased in R6/2 muscle suggesting that the
plantar flexor muscles were fatigued due to repeated stimulation. Since nerve stimulated
contractions were performed prior to direct muscle stimulation, the muscle had contracted
over fifteen times at different frequencies. WT muscle had no problem with this level of
stimulation and the twitch to tetanic ratio was consistent from nerve stimulation to
muscle stimulation in WT muscle. To further assess how prone to fatigue HD muscle is,
repeated stimulation protocols should be developed, and muscle force should be assessed.
With motor dysfunction being the primary symptom of HD and a leading cause of
mortality, skeletal muscle defects are a promising target for the treatment of symptoms in
HD. This work provides additional support for the continued study of primary peripheral
defects in animal models of HD. There is no doubt that cognitive decline and striatal
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degeneration also play a key role in the progression of HD symptoms, but unfortunately
these areas are harder to treat. Even if symptoms could be partially ameliorated and
progression of the disease slowed by some percentage, patient outlook could be
drastically improved.
An essential tool for the development of the muscle force system used to
complete this thesis was the ability to rapidly create various prototypes by utilizing 3D
modeling and printing. There is no doubt that the skills obtained throughout this project
will be used in future endeavors. It is our hope that 3D printing will continue to be
utilized in biological research. Here, we have only scratched the surface of the potential
for this tool to help us further understand human disease.
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